Informations générales (source: ClinicalTrials.gov)
Preliminary Monocentric Study for the Validation of the Circuit of Examinations and Analyzes of Samples in Perspective of Large-scale Application for Better Classification of Airway Diseases (BABY-ROAD)
Observational
Hopital Foch (Voir sur ClinicalTrials)
mai 2023
décembre 2023
26 avril 2025
ADs (airway diseases) are a group of progressive diseases that lead to a decline of lung
function, accelerated by recurrent exacerbations, which can lead to death. ADs include a
number of different conditions including asthma, chronic obstructive pulmonary disease
(COPD), cystic fibrosis (CF), bronchiectasis and bronchiolitis frequently related to
immune difciency or hematopoietic stem cell transplantations (HSCT), and obstructive
chronic lung allograft dysfunction (O-CLAD). The financial burden of ADs is monumental.
It is imperative to prevent exacerbations and decline in lung function to reduce ADs
mortality and morbidity. The vast amount of knowledge accumulated over the last several
years in both biotechnology and digital intelligence, has afforded the evidence of the
presence of various treatable traits spread among ADs, that imposes to reassess ADs.
BABY-ROAD study proposes to take advantage of these advances to test the feasibility of
sampling and exploring ADs patients with multisource data. Baby-ROAD study will be
preliminary to the ROAD study that will propose to reclassify ADs into new clusters
pertinent for preventive, personalized and participative care.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | Antoine MAGNAN | 05/05/2025 07:12:14 | Contacter | ||
Critères
Tous
Inclusion Criteria:
- Adults
- Severe asthmatics + asthmatics previously hospitalized at least once in 2016 - 2019
- COPD patients previously hospitalized at least once in 2016 - 2019 Cystic fibrosis
patients, patients with immunodeficiency, without bone marrow transplantation, and
with AD determined upon bronchial obstruction (FEV1/FVC < 70%).
- Lung transplant recipients with obstructive chronic lung allograft rejection
(O-CLAD)
- Hematopoietic stem cell transplant recipients with AD determined upon bronchial
obstruction.
- Patients already followed-up in pulmonology clinic at the Foch Hospital
- Patients understanding the French language
- Patients having signed an informed consent form prior to any study specific
procedure
- Patients being covered by a national health insurance
- Adults
- Severe asthmatics + asthmatics previously hospitalized at least once in 2016 - 2019
- COPD patients previously hospitalized at least once in 2016 - 2019 Cystic fibrosis
patients, patients with immunodeficiency, without bone marrow transplantation, and
with AD determined upon bronchial obstruction (FEV1/FVC < 70%).
- Lung transplant recipients with obstructive chronic lung allograft rejection
(O-CLAD)
- Hematopoietic stem cell transplant recipients with AD determined upon bronchial
obstruction.
- Patients already followed-up in pulmonology clinic at the Foch Hospital
- Patients understanding the French language
- Patients having signed an informed consent form prior to any study specific
procedure
- Patients being covered by a national health insurance
- COPD patients previously hospitalized but before 2016
- Immunocompromised patients, having had a bone marrow transplant and suffering from
AD determined by bronchial obstruction (FEV1/FVC > 70%).
- Patients weighing less than 50 kg
- Pregnant women
- Patients who are not followed in pulmonology consultation at Foch Hospital
- Patients don't understanding the French language
- Don't being covered by a national health insurance
- Being deprived of liberty or under guardianship